These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 16330291

  • 1. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.
    Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
    [Abstract] [Full Text] [Related]

  • 2. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
    Rosenstock J, Rood J, Cobitz A, Huang C, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
    [Abstract] [Full Text] [Related]

  • 11. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
    Goldstein BJ, Weissman PN, Wooddell MJ, Waterhouse BR, Cobitz AR.
    Curr Med Res Opin; 2006 Sep; 22(9):1715-23. PubMed ID: 16968575
    [Abstract] [Full Text] [Related]

  • 12. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.
    Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ.
    Curr Med Res Opin; 2005 Dec; 21(12):2029-35. PubMed ID: 16368054
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
    Scott R, Loeys T, Davies MJ, Engel SS, Sitagliptin Study 801 Group.
    Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
    [Abstract] [Full Text] [Related]

  • 19. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.
    Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.